我們已在上線!
進一步了解
Anebulo Pharmaceuticals
ANEB
ANEB
已下市
ANEB已於2026年2月27日下市。
關於: Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
員工: 3
新聞
正面
中性
負面
市場情緒
3個月
正面
0%
中性
0%
負面
0%
價格圖表採用Lightweight Charts™實作